CSPC Pharmaceutical Group stock analysis
CSPC Pharmaceutical Group (CVG) Stock Price & Analysis
CVG Stock Chart & Stats
- Day’s Range
- EUR 0.95 - EUR 0.95
- 52-Week Range
- EUR 0.73 - EUR 1.13
- Previous Close
- EUR 0.95
- Volume
- N/A
- Average Volume (3M)
- 332
- Market Cap
- EUR 11.02B
- Enterprise Value
- EUR 61.00B
- Total Cash (Recent Filing)
- EUR 18.48B
- Total Debt (Recent Filing)
- EUR 652.37M
- Price to Earnings (P/E)
- 11.0
- Beta
- 0.23
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.87%
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
Extremely low leverage gives CSPC substantial financial flexibility and reduces interest and refinancing pressure. The conservative capital structure should help the company withstand operating volatility while preserving capacity to fund research, product development, and commercial expansion.
Resilient Profitability
High gross margins and solid operating profitability indicate a valuable pharmaceutical product mix and meaningful earnings resilience. Although performance has moderated, this profitability provides internal funding for innovation and supports competitiveness across domestic and selected international markets.
Improved Cash Generation
The strong 2025 rebound in operating and free cash flow improves CSPC’s ability to finance investment, support operations, and return capital without relying heavily on borrowing. This cash generation is especially valuable alongside the company’s very low leverage and broad equity base.
Bears Say
Soft Revenue Growth
Recent revenue performance shows that CSPC’s top-line momentum has weakened materially from earlier periods. Declines followed by only low-single-digit growth can limit operating leverage, reduce resources available for reinvestment, and make future earnings more dependent on margin recovery or new products.
Margin Compression
The sustained decline in EBIT margin indicates that earlier profitability levels have not been fully maintained. Continued compression would reduce the earnings benefit of future sales growth, constrain internal funding for research and commercialization, and weaken the company’s financial operating leverage.
Lower Return On Equity
Falling ROE suggests CSPC is generating less profit from its substantial capital base than it did previously. Even with conservative financing, weaker capital efficiency can limit long-term earnings compounding and signal that profitability has not kept pace with the company’s equity resources.
CSPC Pharmaceutical Group News
CVG FAQ
What was CSPC Pharmaceutical Group’s price range in the past 12 months?
What is CSPC Pharmaceutical Group’s market cap?
When is CSPC Pharmaceutical Group’s upcoming earnings report date?
How were CSPC Pharmaceutical Group’s earnings last quarter?
Is CSPC Pharmaceutical Group overvalued?
Does CSPC Pharmaceutical Group pay dividends?
What is CSPC Pharmaceutical Group’s EPS estimate?
How many shares outstanding does CSPC Pharmaceutical Group have?
What happened to CSPC Pharmaceutical Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CSPC Pharmaceutical Group?
What is the TipRanks Smart Score and how is it calculated?
CSPC Pharmaceutical Group Stock Smart Score
Company Description
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Lei Cai
- Employees
- 18,626
- Website
- www.cspc.com.hk
- Address
- No. 226 Huanghe Street, Shijiazhuang, HE, 050035, CN
CSPC Pharmaceutical Group (CVG) Earnings & Revenues
CVG Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 5 | 5 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 10 | 0 | 2 |
